7,580.25

+5.75

+0.08%

52,057.00

-76.00

-0.15%

28,232.50

+105.00

+0.37%

Russell 2000 Futures

2,820.80

+3.00

+0.11%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,964.00

-5.60

-0.14%

77,071.47

-1,218.28

-1.56%

Crude Oil Dec 26

96.64

+0.18

+0.19%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqGM - Nasdaq Real Time Price USD

MediciNova, Inc. (MNOV)

1.4400 +0.0400 (+2.86%)

At close: November 2 at 4:00:01 PM EST

Loading Chart for MNOV

Chart Range Bar

Interval:

In partnership with ChartIQ

MediciNova CEO Provides Shareholder Update

MediciNova CEO Provides Shareholder Update

MediciNova to Participate in the Maxim Growth Summit

MediciNova to Participate in the Maxim Growth Summit

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MediciNova to Participate in Two Investor Conferences in September

MediciNova to Participate in Two Investor Conferences in September

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova CEO Provides Shareholder Update

MediciNova CEO Provides Shareholder Update

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

Mobilize your Website

View Site in Mobile | Classic

Share by: